Cite
HARVARD Citation
Chisholm, J. et al. (2018). BRIM‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma. Pediatric blood & cancer. 65 (5), p. n/a. [Online].